

Edgar Filing: NEUROLOGIX INC/DE - Form 8-K

NEUROLOGIX INC/DE
Form 8-K
March 18, 2005

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): March 14, 2005

Neurologix, Inc.
(Exact name of registrant as specified in its charter)

DELAWARE	0-13347	06-1582875
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	I.R.S. Employer Identification No.)

ONE BRIDGE PLAZA, FORT LEE, NEW JERSEY	07024
(Address of principal executive offices)	(Zip Code)

(201) 592-6451

(Registrant's telephone number, including area code)

None

(Former name, former address and former fiscal year,
if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement.

Edgar Filing: NEUROLOGIX INC/DE - Form 8-K

On March 14, 2004, the registrant executed a definitive employment agreement and stock option agreement with its President and Chief Executive Officer, Dr. Michael Sorell. The agreements are retroactively effective as of September 21, 2004 and reflect on all substantive matters the term sheet approved by the registrant's board of directors on September 21, 2004. A summary of the material items of the agreements was included in the Current Report on Form 8-K filed by the registrant on September 24, 2004, which is incorporated herein by reference. Dr. Sorell's employment agreement provides for the issuance of 1,150,000 stock options. Of the total stock options granted, 273,892 stock options were granted out of the remaining shares available for issuance under the registrant's 2000 Stock Option Plan (the "Plan") and although the balance of 876,108 stock options was not granted out of the shares approved by shareholders under the Plan, the stock options are otherwise governed by the terms of the Plan and the stock option agreement. The employment agreement and stock option agreement are filed herewith as Exhibits 10.1 and 10.2, respectively.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

See Exhibit Index below.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEUROLOGIX, INC.

Dated: March 18, 2005

By: /s/ Mark S. Hoffman

Name: Mark S. Hoffman

Title: Secretary and Treasurer

EXHIBIT INDEX

Exhibit No. -----	Description -----
10.1	Employment Agreement with Michael Sorell, M.D. dated as of September 21, 2004
10.2	Stock Option Agreement with Michael Sorell, M.D. dated as of September 21, 2004